Infacare Pharmaceutical (Trevose, PA) a specialty pharma company focused on the the acute neonatal and pediatric care closed a $28M Series financing. Participants include HealthCare Ventures, Longitude Capital, FirstMark Capital and Atlas Venture.

AlloCure (Germany, UT) a cell therapy company focused on acute kidney injury closed a $14.5M Series A financing. Participants include SV Life Sciences and Novo AS.

Cytochroma (Canada) clinical-stage specialty pharmaceutical company focused on products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease, closed a $45M Series C financing. Participants include Mitsubishi Tanabe Pharma Corporation, Vengrowth Advanced Life Sciences Fund, Caisse de Depot et Placement du Quebec, Novo, Canadian Medical Discoveries Fund, T2C2 Capital, GrowthWorks Canadian Fund, [...]

AM-Pharma (Netherlands) biopharmaceutical company developing endogenous proteins and peptides to combat acute renal failure, ulcerative colitis and hospital acquired infections, closed a $36M Series C financing. Participants include Forbion Capital Partners and Inventages Venture Capital.

Quark Pharmaceuticals (Fremont, CA) development-stage pharmaceutical company focused on discovering and developing novel RNAi therapeutics, closed a $27M Series B financing. Participants include SBI Investment Co.

Stromedix (Cambridge, MA) development-stage biotechnology company focused on therapies for fibrosis, closed a $25M Series B financing. Participants include New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, Atlas Venture and Frazier Healthcare Ventures.

Pervasis Therapeutics (Cambridge, MA) is working to regulate vascular repair and restore natural blood flow to critical organs in end-stage renal disease closed a $9.75M Series B financing. Participants include Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates.